Pharmacokinetics Modeling and Simulation of Voriconazole Dosing and Safety in Patients with Liver Cirrhosis

Wang, T.; Yan, M.; Tang, D.; Dong, Y.; Zhu, L.; Du, Q.; Sun, D.; Xing, J.

doi:10.1101/563528

Home/Archive/bioRxiv

bioRxiv · 10.1101/563528

Pharmacokinetics Modeling and Simulation of Voriconazole Dosing and Safety in Patients with Liver Cirrhosis

Wang, T.·Yan, M.·Tang, D.·Dong, Y.·Zhu, L.·Du, Q.·Sun, D.·Xing, J.

View original source ↗Export metadata ↓

Abstract

Voriconazole is used to treat invasive fungal disease and the optimal dose regimens are still unknown in cirrhotic Patients. The aim of this study was to determine the safety, to describe pharmacokinetics characteristics, and to optimize dosage regimens of voriconazole in cirrhotic patients. Data pertaining to voriconazole were collected retrospectively and analyzed using a population pharmacokinetics model. A total of 219 trough concentrations (Cmin) from 120 patients were analyzed. Voriconazole-related adverse events developed in 29 patients, with 69.0% of AEs developing within the first week after voriconazole treatment. The threshold Cmin for AEs was 5.12 mg/L. A one-compartment model with first-order absorption and elimination adequately described the data. The Child-Pugh class was the only covariate in final model. Voriconazole clearance in patients with Child-pugh A and B cirrhosis (CP-A/CP-B) and Child-pugh C cirrhosis (CP-C) were 1.79 L/h and 0.99 L/h, respectively, the volume of distribution was 159.6 L, and the oral bioavailability was 91.8%. The elimination half-life was significantly extended for up to 61.8 - 111.7 h in cirrhotic patients. Model-based simulations showed that the appropriate maintenance doses are 75 mg/12 h and 150 mg/24 h intravenously or orally for CP-A/CP-B patients, and 50 mg/12 h and 100 mg/24 h intravenously or orally for CP-C patients. The results support voriconazole maintenance doses in LC patients should be reduced to one-fourth for CP-C patients and to one-third for CP-A/CP-B patients compared to that for patients with normal liver function. Monitoring Cmin early could be a useful strategy to ensure the safety.

Explore related subjects

pharmacology and toxicology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Wang, T., Yan, M., Tang, D., Dong, Y., Zhu, L., Du, Q., Sun, D., Xing, J.. 2019-02-28. Pharmacokinetics Modeling and Simulation of Voriconazole Dosing and Safety in Patients with Liver Cirrhosis. https://doi.org/10.1101/563528

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

bioRxiv2026

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

bioRxiv2019

Fentanyl depression of respiration: comparison with heroin and morphine

Background and PurposeFentanyl overdose deaths have reached epidemic levels in North America. Death in opioid overdose invariably results from respiratory depression. In the present work we have characterized how fentanyl depresses respiration and by comparing fentanyl with heroin and morphine, the active breakdown product of heroin, we have sought to determine whether there are factors, in addition to high potency, that contribute to the lethality of fentanyl.\n\nExperimental ApproachRespiration (rate and tidal volume) was measured in awake, freely moving mice by whole body plethysmography\n\nKey ResultsIntravenously administered fentanyl produced more rapid depression of respiration than equipotent doses of heroin or morphine. Fentanyl depressed both respiratory rate and tidal volume, the effect on tidal volume may reflect increased respiratory muscle stiffness. Fentanyl did not depress respiration in opioid receptor knock-out mice. Naloxone, the opioid antagonist widely used to treat opioid overdose, reversed the depression of respiration by morphine more readily than that by fentanyl whereas diprenorphine, a more lipophilic antagonist, was equipotent in reversing fentanyl and morphine depression of respiration. Prolonged treatment with morphine induced tolerance to respiratory depression but the degree of cross tolerance to fentanyl was less than the tolerance to morphine itself.\n\nConclusion and ImplicationsWe propose that several factors (potency, rate of onset, muscle stiffness, lowered sensitivity to naloxone and lowered cross tolerance to morphine) combine to make fentanyl more likely to cause opioid overdose deaths than other commonly abused opioids.

pharmacology and toxicology↗